Filing Flows › Tactile Systems Technology (TCMD) › Lymphedema products revenue
Tactile Systems Technology (TCMD) Lymphedema products revenue by quarter
Tactile Systems Technology's Lymphedema products revenue was $81.8M in Q3 2026 (third quarter 2026), +11% from Q2 2026. Over the last 7 quarters it ranged from $50.6M (Q1 2025) to $89.5M (Q4 2025).
| Quarter | Lymphedema products revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $81.8M | +11% | +13% |
| Q2 2026 | $73.6M | +18% | +12% |
| Q1 2026 | $62.2M | -30% | +23% |
| Q4 2025 | $89.5M | +24% | — |
| Q3 2025 | $72.4M | +10% | — |
| Q2 2025 | $66.0M | +30% | — |
| Q1 2025 | $50.6M | — | — |
Q3 2026 at a glance
Tactile Systems Technology, Q3 2026: revenue $91.9M (+7% year over year), operating margin 10.4%, net earnings $7.2M, operating cash flow $12.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Tactile Systems Technology's Lymphedema products revenue?
Tactile Systems Technology's Lymphedema products revenue was $81.8M in Q3 2026 (third quarter 2026), +11% from Q2 2026.
How has Tactile Systems Technology's Lymphedema products revenue changed?
Over the last 7 quarters it ranged from $50.6M (Q1 2025) to $89.5M (Q4 2025).
Q3 2026 results → · How Tactile Systems Technology makes money →